Advanta V12
Advanta V12
Balloon expandable covered stent
Trusted. Reliable. Proven.
Overview
For more than 15 years, by touching over 500,000 lives, our Advanta V12 balloon expandable covered stent has been trusted by physicians for its ease of use and proven, reliable outcomes.
Designed with a unique PTFE covering technology, Advanta V12 inspires confidence with high patency and low reintervention rates.[1] Backed by robust, long-term clinical data and over 450 publications, the Advanta V12 stent continues to prove itself every day.
Indications:
The Advanta V12 balloon expandable covered stent is CE marked and TGA approved for restoring and improving the patency of iliac and renal arteries. Advanta V12 has Canadian Health Ministry license for restoring the patency of iliac lesions. Renal approval is for 5 mm to 7 mm sizes. Advanta V12 is not available in the U.S.
PTFE Film Covering Technology
The ultra-thin covering of the Advanta V12 uses a unique, proprietary PTFE film covering technology. The 316L stainless steel struts are completely covered protecting both the flow lumen as well as the struts from contacting the luminal wall. The Advanta V12 is designed to expand uniformly and prevent tissue from prolapsing through the expanded stent.
Product Features
Conformable, deliverable, flexible
Designed to track through tortuous arteries and flex to accommodate the iliac and renal anatomy
Low Profile
6F & 7F compatibility offers versatility and efficient delivery in complex endovascular procedures
Ability to post-dilate
Allows a customized solution to various anatomy*
*Post dilation should always be performed following the guidelines within the Advanta V12 covered stent IFU.
Trusted Design
Advanta V12 was designed to conform to the vessel structure, flexible enough to be navigated to the iliac anatomy and to accommodate a 90-degree bend*.
*8-10mm diameters only.
Clinical Data
COBEST - Randomized Multicenter Study Advanta V12 vs Bare Metal Stents
5-Year Data
- Two-fold lower incidence of re-intervention (p=.02)
- Significantly higher patency rates at 5 years (74.7% vs. 62.9%; p=.01)[1]
- Significantly higher patency in subgroup analysis of TASC C/D lesions (p=.003) [1]
iCARUS: Single-Arm IDE Study with 3-Year Follow-Up
Freedom from Target Lesion Revascularization (TLR)
- Real-world patient population with multiple lesions and bilateral disease
- Study showed sustained clinical benefit with freedom from target lesion revascularization (TLR) up to 3 years[2]